Drugs / RLS-1496
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07340697 | Jan → Apr 2026 overdue | actinic keratosis | Rubedo Life Sciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLS-1496 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07340697 ↗ |
| Route | Topical | “Topical cream to be applied to lesions and peri-lesional skin.” NCT07340697 ↗ |